Provided by Tiger Fintech (Singapore) Pte. Ltd.

VYNE Therapeutics Inc.

0.9141
+0.02412.71%
Post-market: 0.9100-0.0041-0.45%19:29 EDT
Volume:158.89K
Turnover:144.07K
Market Cap:15.23M
PE:-0.92
High:0.9300
Open:0.8900
Low:0.8900
Close:0.8900
Loading ...

VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating

TIPRANKS
·
09 May

Vyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

VYNE Therapeutics reports Q1 EPS (20c) vs (15c) last year

TIPRANKS
·
08 May

VYNE Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate, Sales $202.00K Beat $50.00K Estimate

Benzinga
·
08 May

BRIEF-VYNE Therapeutics Q1 Basic EPS USD -0.2

Reuters
·
08 May

Vyne Therapeutics Q1 Basic EPS USD -0.2

THOMSON REUTERS
·
08 May

Vyne Therapeutics Q1 Revenue USD 202 Thousand

THOMSON REUTERS
·
08 May

Vyne Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
05 May

Vyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
25 Apr

Vyne Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $4.5 From $5.75

THOMSON REUTERS
·
25 Apr

VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell

MT Newswires Live
·
25 Apr

Vyne Therapeutics Inc - Clinical Hold Does Not Affect Phase 2B Trial of Repibresib Gel

THOMSON REUTERS
·
25 Apr

VYNE Therapeutics Provides Update on VYN202 Program

GlobeNewswire
·
25 Apr

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire
·
20 Mar

VYNE Therapeutics Reports Progress in Clinical Trials

TIPRANKS
·
08 Mar

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)

TIPRANKS
·
07 Mar

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
07 Mar

Buy Rating for VYNE Therapeutics Driven by Strong Financial Health and Promising Pipeline Developments

TIPRANKS
·
07 Mar

VYNE Therapeutics: Strong Financials and Promising Clinical Developments Reinforce Buy Rating

TIPRANKS
·
06 Mar

Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar